Skip to main content

Advertisement

SpringerLink
Log in

Clinical efficacy of topical nipradilol and timolol on visual field performance in normal-tension glaucoma: a multicenter, randomized, double-masked comparative study

  • Clinical Investigation
  • Published:
Japanese Journal of Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To compare the effects of topical nipradilol and timolol on the visual field in Japanese normaltension glaucoma (NTG) patients.

Methods

We enrolled 146 NTG patients. At baseline, age, intraocular pressure (IOP), and mean deviation (MD) by the Humphrey field analyzer were 47.6 (SD 8.5), 14.2 (1.7) mmHg, and −4.5 (3.0) dB. Seventy-two patients were randomly assigned to the 0.25% nipradilol group and 74 patients to the 0.5% timolol ophthalmic solution group twice daily for the 3-year study period. The Humphrey full-threshold 30-2 visual field test was performed every 6 months. The primary end point was the nonparametric O’Brien summary score (sum of the ranks of six slopes calculated from the average of the total deviation in each cluster) in each patient. The secondary analyses were differences in the MD slope, average of the total deviation in each cluster, the corrected pattern standard deviation (CPSD), and the time course of IOP.

Results

No significant intergroup differences were found in baseline characteristics, or in the parameters of the primary and secondary analyses. In both groups, central superior clusters showed negative slopes and IOP decreased by about 1 mmHg from baseline.

Conclusion

No significant difference in visual field performance or IOP reduction was seen between the nipradilol and timolol groups.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressure. Am J Ophthalmol 1998;126:487–497.

    Article  Google Scholar 

  2. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998;126:498–505.

    Article  Google Scholar 

  3. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429–440.

    Article  Google Scholar 

  4. Lichter PR, Musch DC, Gillespie BW, et al. CIGTS Study Group. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001;108:1943–1953.

    Article  CAS  PubMed  Google Scholar 

  5. Heijl A, Leske MC, Bengtsson B, et al. The Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression. Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268–1279.

    Article  PubMed  Google Scholar 

  6. Anderson DR. The damage caused by pressure. XLVI Edward Jackson Memorial Lecture. Am J Ophthalmol 1989;108:485–495.

    Article  CAS  PubMed  Google Scholar 

  7. Fechtner RD, Weinreb RN. Mechanisms of optic nerve damage in primary open-angle glaucoma. Surv Ophthalmol 1994;39:23–42.

    Article  CAS  PubMed  Google Scholar 

  8. Araie M, Azuma I, Kitazawa Y. Influence of topical betaxolol and timolol on visual field in Japanese open-angle glaucoma patients. Jpn J Ophthalmol 2003;47:199–207.

    Article  CAS  PubMed  Google Scholar 

  9. Kitazawa Y, Shirai H, Go FJ. The effect of Ca2+-antagonist on visual field in low-tension glaucoma. Graefes Arch Clin Exp Ophthalmol 1989;227:408–412.

    Article  CAS  PubMed  Google Scholar 

  10. Sawada A, Kitazawa Y, Yamamoto T, Okabe I, Ichien K. Prevention of visual field defect progression with brovincamine in eyes with normal-tension glaucoma. Ophthalmology 1996;103:283–288.

    Article  CAS  PubMed  Google Scholar 

  11. Koseki N, Araie M, Yamagami J, Shirato S, Yamamoto S. Effects of oral brovincamine on visual field damage in patients with normal-tension glaucoma with low-normal intraocular pressure. J Glaucoma 1999;8:117–123.

    Article  CAS  PubMed  Google Scholar 

  12. Uchida Y, Nakamura M, Shimizu S, Fujii M. Vasoactive and β-adrenoceptor blocking properties of 3,4-dihydro-8-(2-hydroxy-3-isopropylamino) propoxy-3-nitroxy-2H-1-benzopyran (K-351), a new antihypertensive agent. Arch Int Pharmacodyn 1983;262:132–149.

    CAS  PubMed  Google Scholar 

  13. Ohira A, Wada Y, Fujii M, et al. Effects of nipradilol (K-351) on alpha-adrenoceptor mediated responses in various isolated tissues. Arch Int Pharmacodyn 1985;278:61–71.

    CAS  PubMed  Google Scholar 

  14. Kanno M, Araie M, Tomita K, Sawanobori K. Effects of topical nipradilol, a β-blocking agent with α-blocking and nitroglycerinlike activities, on aqueous humor dynamics and fundus circulation. Invest Ophthalmol Vis Sci 1998;39:736–743.

    CAS  PubMed  Google Scholar 

  15. Kanno M, Araie M, Koibuchi H, Masuda K. Effects of topical nipradilol, a β blocking agent with α blocking and nitroglycerin-like activities, on intraocular pressure and aqueous dynamics in humans. Br J Ophthalmol 2000;84:293–299.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Kanno M, Araie M, Masuda K, et al. Phase III long-term study and comparative clinical study of nipradilol ophthalmic solution in patients with primary open-angle glaucoma and ocular hypertension. Arzneimittelforschung 2006;56:729–734.

    CAS  PubMed  Google Scholar 

  17. Kanno M, Araie M, Masuda K, et al. Phase III long-term study and comparative clinical study of nipradilol ophthalmic solution in patients with primary open-angle glaucoma and ocular hypertension. Arzneimittelforschung 2006;56:820–825.

    CAS  PubMed  Google Scholar 

  18. Mizuno K, Koide T, Yoshimura M, Araie M. Neuroprotective effect and intraocular penetration of nipradilol, a β-blocker with nitric oxide donative action. Invest Ophthalmol Vis Sci 2001;42:688–694.

    CAS  PubMed  Google Scholar 

  19. Kashiwagi K, Iizuka Y, Tsukahara S. Neuroprotective effects of nipradilol on purified cultured retinal ganglion cells. J Glaucoma 2002;11:231–238.

    Article  PubMed  Google Scholar 

  20. Mizuno K, Koide T, Saito N, et al. Topical nipradilol: effects on optic nerve head circulation in humans and periocular distribution in monkeys. Invest Ophthalmol Vis Sci 2002;43:3243–3250.

    PubMed  Google Scholar 

  21. Matts JP, Lachin JM. Properties of permuted-block randomization in clinical trials. Control Clin Trials 1988;9:327–344.

    Article  CAS  PubMed  Google Scholar 

  22. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:714–720.

    Article  PubMed  Google Scholar 

  23. O’Brien PC. Procedures for comparing samples with multiple endpoints. Biometrics 1984;40:1079–1087.

    Article  PubMed  Google Scholar 

  24. Suzuki Y, Kitazawa Y, Araie M, et al. Mathematical and optimal clustering of test points of the central 30-degree visual field of glaucoma. J Glaucoma 2001;10:121–128.

    Article  CAS  PubMed  Google Scholar 

  25. Mayama C, Araie M, Suzuki Y, et al. Statistical evaluation of the diagnostic accuracy of methods used to determine the progression of visual field defects in glaucoma. Ophthalmology 2004;111:2117–2125.

    Article  PubMed  Google Scholar 

  26. Shigeeda T, Tomidokoro A, Araie M, Koseki N, Yamamoto S. Long-term follow-up of visual field progression after trabeculectomy in progressive normal-tension glaucoma. Ophthalmology 2002;109:766–770.

    Article  PubMed  Google Scholar 

  27. Nakazawa T, Tomita H, Yamaguchi K, et al. Neuroprotective effect of nipradilol on axotomized rat retinal ganglion cells. Curr Eye Res 2002;24:114–122.

    Article  PubMed  Google Scholar 

  28. Taniai M, Sato E, Mizota A, Adachi-Usami E. Protective action of nipradilol against ischemia-induced retinal damage in rats. Ophthalmic Res 2002;34:331–337.

    Article  CAS  PubMed  Google Scholar 

  29. Tomita H, Nakazawa T, Sugano E, Abe T, Tamai M. Nipradilol inhibits apoptosis by preventing the activation of caspase-3 via S-nitrosylation and the cGMP-dependent pathway. Eur J Pharmacol 2002:452:263–268.

    Article  CAS  PubMed  Google Scholar 

  30. Ando A, Yamazaki Y, Kaneko S, et al. Cytoprotection by nipradilol, an anti-glaucomatous agent, via down-regulation of apoptosis related gene expression and activation of NF-κB. Exp Eye Res 2005;80:501–507.

    Article  CAS  PubMed  Google Scholar 

  31. Osborne NN, Cazevieille C, Carvalho AL, Larsen AK, DeSantis L. In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent. Brain Res 1997;751:113–123.

    Article  CAS  PubMed  Google Scholar 

  32. Gross RL, Hensley SH, Gao F, Wu SM. Retinal ganglion cell dysfunction induced by hypoxia and glutamate: potential neuroprotective effects of β-blockers. Surv Ophthalmol 1999;43Suppl 1:S162–170.

    Article  PubMed  Google Scholar 

  33. Acheampong AA, Shackleton M, John B, Burke J, Wheeler L, Tang-Liu D. Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes. Drug Metab Dispos 2002;30:421–429.

    Article  CAS  PubMed  Google Scholar 

  34. Ichikawa M, Okada Y, Asai Y, Hara H, Ishii K, Araie M. Effects of topically instilled bunazosin, an α1-adrenoceptor antagonist, on constrictions induced by phenylephrine and ET-1 in rabbit retinal arteries. Invest Ophthalmol Vis Sci 2004;45:4041–4048.

    Article  PubMed  Google Scholar 

  35. Anderson DR, Drance SM, Schulzer M; Collaborative Normal-Tension Glaucoma Study Group. Natural history of normal-tension glaucoma. Ophthalmology 2001;108:247–253.

    Article  CAS  PubMed  Google Scholar 

  36. Tomita G, Araie M, Kitazawa Y, Tsukahara S. A three-year prospective, randomized and open comparison between latanoprost and timolol in Japanese normal-tension glaucoma patients. Eye 2004;18:984–989.

    Article  CAS  PubMed  Google Scholar 

  37. Goto W, Ota T, Morikawa N, et al. Protective effects of timolol against the neuronal damage induced by glutamate and ischemia in the rat retina. Brain Res 2002;958:10–19.

    Article  CAS  PubMed  Google Scholar 

  38. Chen YN, Yamada H, Mao W, Matsuyama S, Aihara M, Araie M. Hypoxia-induced retinal ganglion cell death and the neuroprotective effects of β-adrenergic antagonists. Brain Res 2007;1148:28–37.

    Article  CAS  PubMed  Google Scholar 

  39. Werner EB, Drance SM. Early visual field disturbances in glaucoma. Arch Ophthalmol 1977;95:1173–1175.

    Article  CAS  PubMed  Google Scholar 

  40. Hart WM Jr, Becker B. The onset and evolution of glaucomatous visual field defects. Ophthalmology 1982;89:268–279.

    Article  PubMed  Google Scholar 

  41. Yamada Y, Takayanagi R, Tsuchiya K, et al. Assessment of systemic adverse reactions induced by ophthalmic β-adrenergic receptor antagonists. J Ocul Pharmacol Ther 2001;17:235–248.

    Article  CAS  PubMed  Google Scholar 

  42. Yamada Y, Takayanagi R, Ozeki T, Yokoyama H, Iga T, Araie M. Predicting systemic adverse effects associated with nipradilol ophthalmic solution based on β-receptor occupancy. Atarashii Ganka (J Eye) 2006;23:87–94.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, University of Tokyo Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan

    Makoto Araie

  2. Yotsuya-Shirato Eye Clinic, Shinjuku-ku, Tokyo, Japan

    Shiroaki Shirato

  3. Department of Ophthalmology, Nihon University School of Medicine, Itabashi-ku, Tokyo, Japan

    Yoshio Yamazaki

  4. Akasaka Kitazawa Eye Clinic, Minato-ku, Tokyo, Japan

    Yoshiaki Kitazawa

  5. Department of Biostatistics, School of Public Health, University of Tokyo, Bunkyo-ku, Tokyo, Japan

    Yasuo Ohashi

Authors
  1. Makoto Araie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shiroaki Shirato
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yoshio Yamazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoshiaki Kitazawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yasuo Ohashi
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

the Nipradilol-Timolol Study Group

Corresponding author

Correspondence to Makoto Araie.

About this article

Cite this article

Araie, M., Shirato, S., Yamazaki, Y. et al. Clinical efficacy of topical nipradilol and timolol on visual field performance in normal-tension glaucoma: a multicenter, randomized, double-masked comparative study. Jpn J Ophthalmol 52, 255–264 (2008). https://doi.org/10.1007/s10384-008-0540-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10384-008-0540-z

Key Words

Search

Navigation